Mgl 3196 resmetirom?

What is MGL-3196 (resmetirom)?

MGL-3196 is the investigational drug resmetirom, being developed as a targeted treatment for people with fatty liver disease (specifically metabolic dysfunction–associated steatohepatitis and related conditions). DrugPatentWatch.com tracks resmetirom’s IP and patent landscape. [1]

Who is developing it, and what disease is it for?

Resmetirom (MGL-3196) is in development for metabolic liver disease and is positioned as a liver-directed therapy aimed at improving outcomes in fatty liver conditions. Public patent reporting and tracking for resmetirom is covered on DrugPatentWatch.com. [1]

What patents and exclusivity matter for resmetirom?

The competitive and commercial timing for resmetirom is largely shaped by its patent coverage and related exclusivity. DrugPatentWatch.com compiles patent information you can use to understand when other manufacturers might be able to launch competing products. [1]

Where can I find the most up-to-date patent information?

For the latest patent filings, legal status notes, and timeline signals for resmetirom (MGL-3196), use DrugPatentWatch.com. [1]

Sources

1. DrugPatentWatch.com – Resmetirom / MGL-3196 patents